Oxurion NV (0G99)

0.02
0.00(11.11%)
  • Volume:
    184,776
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    0.02 - 0.02

0G99 Overview

Prev. Close
0.02
Day's Range
0.02-0.02
Revenue
398K
Open
0.02
52 wk Range
0.01-1.99
EPS
-0.759
Volume
184,776
Market Cap
5.23M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
305,887
P/E Ratio
-0.514
Beta
0.889
1-Year Change
-98.92%
Shares Outstanding
311,281,644
Next Earnings Date
24 Mar 2023
What is your sentiment on Oxurion?
or
Market is currently closed. Voting is open during market hours.

Oxurion NV News

  • Oxurion Earnings miss, Revenue beats In Q2
    • ByInvesting.com-

    Investing.com - Oxurion reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations. Oxurion announced earnings per share...

Oxurion NV Company Profile

Oxurion NV Company Profile

Employees
42
Market
Belgium

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyBuyNeutralStrong SellSell
SummaryNeutralNeutralSellStrong SellStrong Sell
  • Is this a bull phase? Or will it crash back to earth? My guess is €1.25 by 01/12/22
    0
    • Ceo Patrick de haes needs to resign. Jetrea commercial flop followed by clinical failure after clinical failure.
      0